Priyanka Aswal*
Artificial intelligence, predictive, and other superior technologies are speedily being integrated into pharmaceutical companies across the world. The interest in AI-centered solutions for early at the time of drug invention is steadily picking momentum among biopharma in which there is a projected market volume of approximately $10B by 2024 across all AI-driven medical diagnostics, medical imaging, drug discovery, genomics, and personal AI assistants. In the past few years, there has been a tremendous wave of modern R and D partnerships between potential biopharma stakeholders and AI-based corporates, especially the startups. Since the majorities of AI-centered companies maximize various techniques of and use interdisciplinary sources of data in modeling their work, the paper looks into different ways AI can be used in the pharmaceutical industry.